Recent Advances in Immunotherapy in Metastatic NSCLC.
Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor typ...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00239/full |
| _version_ | 1818450013193240576 |
|---|---|
| author | Pranshu Bansal Diaa Osman Gregory N Gan George R Simon Yanis Boumber |
| author_facet | Pranshu Bansal Diaa Osman Gregory N Gan George R Simon Yanis Boumber |
| author_sort | Pranshu Bansal |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of PD-1 inhibitors, nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer. |
| first_indexed | 2024-12-14T20:44:33Z |
| format | Article |
| id | doaj.art-d76f8172314d460ca879354d4c976ff6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T20:44:33Z |
| publishDate | 2016-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d76f8172314d460ca879354d4c976ff62022-12-21T22:48:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2016-11-01610.3389/fonc.2016.00239220253Recent Advances in Immunotherapy in Metastatic NSCLC.Pranshu Bansal0Diaa Osman1Gregory N Gan2George R Simon3Yanis Boumber4University of New Mexico Comprehensive Cancer CenterUniversity of New Mexico Comprehensive Cancer CenterUniversity of New Mexico comprehensive cancer centerUniversity of Texas MD Anderson Cancer CenterUniversity of New Mexico Comprehensive Cancer CenterNon-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of PD-1 inhibitors, nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer.http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00239/fullcancer immunotherapyNSCLCPDL1PD1CTLA4Combination immunotherapy |
| spellingShingle | Pranshu Bansal Diaa Osman Gregory N Gan George R Simon Yanis Boumber Recent Advances in Immunotherapy in Metastatic NSCLC. Frontiers in Oncology cancer immunotherapy NSCLC PDL1 PD1 CTLA4 Combination immunotherapy |
| title | Recent Advances in Immunotherapy in Metastatic NSCLC. |
| title_full | Recent Advances in Immunotherapy in Metastatic NSCLC. |
| title_fullStr | Recent Advances in Immunotherapy in Metastatic NSCLC. |
| title_full_unstemmed | Recent Advances in Immunotherapy in Metastatic NSCLC. |
| title_short | Recent Advances in Immunotherapy in Metastatic NSCLC. |
| title_sort | recent advances in immunotherapy in metastatic nsclc |
| topic | cancer immunotherapy NSCLC PDL1 PD1 CTLA4 Combination immunotherapy |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00239/full |
| work_keys_str_mv | AT pranshubansal recentadvancesinimmunotherapyinmetastaticnsclc AT diaaosman recentadvancesinimmunotherapyinmetastaticnsclc AT gregoryngan recentadvancesinimmunotherapyinmetastaticnsclc AT georgersimon recentadvancesinimmunotherapyinmetastaticnsclc AT yanisboumber recentadvancesinimmunotherapyinmetastaticnsclc |